Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.

Lancet. 2012 Aug 11;380(9841):565-71. doi: 10.1016/S0140-6736(12)61190-8.

2.
3.
4.

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.

Kones R.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21. Review.

PMID:
19460829
5.

Statins for primary prevention of venous thromboembolism.

Li L, Zhang P, Tian JH, Yang K.

Cochrane Database Syst Rev. 2014 Dec 18;(12):CD008203. doi: 10.1002/14651858.CD008203.pub3. Review.

PMID:
25518837
7.

Efficacy and safety of rosuvastatin in the management of dyslipidemia.

Rubba P, Marotta G, Gentile M.

Vasc Health Risk Manag. 2009;5(1):343-52. Epub 2009 Apr 8. Review.

8.
9.

Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.

Long SB, Blaha MJ, Blumenthal RS, Michos ED.

Clin Interv Aging. 2011;6:27-35. doi: 10.2147/CIA.S8101. Epub 2010 Dec 22. Review.

10.

Moving toward new statin guidelines in a post-JUPITER world: principles to consider.

Ridker PM.

Curr Atheroscler Rep. 2009 Jul;11(4):249-56. Review.

PMID:
19500487
11.

Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.

Kostapanos MS, Milionis HJ, Elisaf MS.

Am J Cardiovasc Drugs. 2010;10(1):11-28. doi: 10.2165/13168600-000000000-00000. Review.

PMID:
20104931
12.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
13.

An update on the benefits and risks of rosuvastatin therapy.

Toth PP.

Postgrad Med. 2014 Mar;126(2):7-17. doi: 10.3810/pgm.2014.03.2736. Review.

PMID:
24685964
14.

Statin-associated incident diabetes: a literature review.

Park ZH, Juska A, Dyakov D, Patel RV.

Consult Pharm. 2014;29(5):317-34. doi: 10.4140/TCP.n.2014.317. Review.

PMID:
24849689
15.

The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

O'Keefe JH, Carter MD, Lavie CJ, Bell DS.

Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Review.

PMID:
19491548
17.

Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?

Efthimiadis A.

Angiology. 2008 Apr-May;59(2 Suppl):62S-4S. doi: 10.1177/0003319708321668. Epub 2008 Jul 15. Review.

PMID:
18628276
18.

The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.

PMID:
19593321
19.

The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.

Narla V, Blaha MJ, Blumenthal RS, Michos ED.

Vasc Health Risk Manag. 2009;5:1033-42. Epub 2009 Dec 29. Review.

20.

Statins for primary prevention of venous thromboembolism.

Li L, Sun T, Zhang P, Tian J, Yang K.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD008203. doi: 10.1002/14651858.CD008203.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;12:CD008203.

PMID:
22161421

Supplemental Content

Support Center